Ruxolitinib in the Treatment of Vitiligo. The Importance of the JAK STAT Pathway

Related Experiment Video

Updated: Jan 9, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K

J L López Estebaranz1, G Segurado Miravalles2, S Ros Abarca3

  • 1Servicio de Dermatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.

Actas Dermo-Sifiliograficas
|December 10, 2025
PubMed

Insights

Topical ruxolitinib, a JAK 1/2 inhibitor, effectively treats facial vitiligo by targeting the JAK-STAT pathway. This therapy halts disease progression and promotes skin repigmentation in eligible patients.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Vitiligo is a chronic autoimmune condition causing skin depigmentation due to melanocyte loss.
  • The JAK-STAT pathway is implicated in the immunopathogenesis of vitiligo.
  • While historically considered difficult to treat, advancements offer therapeutic options.

Purpose of the Study:

  • To review the immunopathologic mechanisms of vitiligo.
  • To examine the role of the JAK-STAT pathway in vitiligo.
  • To evaluate the efficacy and safety of topical ruxolitinib for nonsegmental vitiligo.

Main Methods:

  • Narrative review of existing literature.
  • Focus on ruxolitinib as a Janus kinase (JAK) 1/2 inhibitor.
  • Analysis of studies concerning adult and adolescent patients (over 12 years) with facial vitiligo.

Main Results:

  • Ruxolitinib is the first topical JAK inhibitor approved for vitiligo treatment.
  • Demonstrated efficacy in halting vitiligo progression and inducing repigmentation.
  • Safety profile and tolerability in the target patient population were assessed.

Conclusions:

  • Topical ruxolitinib represents a significant therapeutic advance for nonsegmental facial vitiligo.
  • Targeting the JAK-STAT pathway offers a viable treatment strategy.
  • Further research should consider psychological impacts and quality of life improvements.
Keywords:
DepigmentationJAK-STATQuality of lifeRepigmentationRuxolitinib creamVitiligo

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K
Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

6.0K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Role of Skin in Vitamin D Synthesis01:23

Role of Skin in Vitamin D Synthesis

The skin plays a crucial role in the synthesis of vitamin D, a vital nutrient for various physiological processes in the body. Vitamin D is unique because it can be synthesized in the skin through a series of chemical reactions triggered by exposure to ultraviolet B (UVB) radiation from sunlight.
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
7.5K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.7K